Literature DB >> 15179540

Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia.

Igor Elman1, David Rott, Alan I Green, Daniel D Langleben, Scott E Lukas, David S Goldstein, Alan Breier.   

Abstract

RATIONALE: Several lines of evidence suggest that the pathophysiology of schizophrenia may be associated with altered noradrenergic and glucoregulatory function.
OBJECTIVE: The aim of this study was to investigate these alterations during a perturbed homeostatic state.
METHODS: Fifteen patients with schizophrenia and 13 healthy individuals were given a glucose deprivation challenge through administration of pharmacological doses of 2-deoxyglucose (2DG; 40 mg/kg), and their plasma was assayed over the next 60 min for concentrations of norepinephrine (NE), the intraneuronal NE metabolite dihydroxyphenylglycol (DHPG), epinephrine and glucose.
RESULTS: 2DG induced significant increases in plasma NE, epinephrine and glucose levels in both groups with significantly greater NE and glucose increments in patients than in controls. For DHPG, 2DG produced increases in patients and decreases in the control subjects. NE responses correlated positively and significantly with the DHPG and glucose responses in schizophrenics, but not in controls.
CONCLUSIONS: These findings suggest that patients with schizophrenia have exaggerated NE and glucose responses to an acute metabolic perturbation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15179540     DOI: 10.1007/s00213-004-1890-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  68 in total

Review 1.  Health and fitness series--1. The importance of physical activity for health.

Authors:  Samantha Stear
Journal:  J Fam Health Care       Date:  2003

2.  Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase.

Authors:  G Eisenhofer; D S Goldstein; R Stull; H R Keiser; T Sunderland; D L Murphy; I J Kopin
Journal:  Clin Chem       Date:  1986-11       Impact factor: 8.327

3.  Portal vein afferents are critical for the sympathoadrenal response to hypoglycemia.

Authors:  A L Hevener; R N Bergman; C M Donovan
Journal:  Diabetes       Date:  2000-01       Impact factor: 9.461

4.  Diabetes mellitus in schizophrenic patients.

Authors:  S Mukherjee; P Decina; V Bocola; F Saraceni; P L Scapicchio
Journal:  Compr Psychiatry       Date:  1996 Jan-Feb       Impact factor: 3.735

Review 5.  Physical consequences of schizophrenia and its treatment: the metabolic syndrome.

Authors:  Martina C M Ryan; Jogin H Thakore
Journal:  Life Sci       Date:  2002-06-07       Impact factor: 5.037

Review 6.  Glucose metabolism in relation to schizophrenia and antipsychotic drug treatment.

Authors:  D S Dwyer; R J Bradley; A S Kablinger; A M Freeman
Journal:  Ann Clin Psychiatry       Date:  2001-06       Impact factor: 1.567

7.  Norepinephrine in chronic paranoid schizophrenia: above-normal levels in limbic forebrain.

Authors:  I J Farley; K S Price; E McCullough; J H Deck; W Hordynski; O Hornykiewicz
Journal:  Science       Date:  1978-04-28       Impact factor: 47.728

8.  Guanethidine blocks the 2-deoxy-D-glucose-induced hypothalamic noradrenergic drive to hyperglycemia.

Authors:  L H Storlien; H S Grunstein; G A Smythe
Journal:  Brain Res       Date:  1985-05-27       Impact factor: 3.252

9.  Effect of long-term neuroleptic treatment on prolactin and norepinephrine levels in serum of chronic schizophrenics: relations to psychopathology and extrapyramidal symptoms.

Authors:  D Naber; C Finkbeiner; B Fischer; K J Zander; M Ackenheil
Journal:  Neuropsychobiology       Date:  1980       Impact factor: 2.328

10.  The effect of 2-deoxy-D-glucose and D-glucose on the efferent discharge rate of sympathetic nerves.

Authors:  A Niijima
Journal:  J Physiol       Date:  1975-09       Impact factor: 5.182

View more
  5 in total

Review 1.  Toward a model of memory enhancement in schizophrenia: glucose administration and hippocampal function.

Authors:  William S Stone; Larry J Seidman
Journal:  Schizophr Bull       Date:  2007-05-15       Impact factor: 9.306

2.  Finding a Panacea among combination cancer therapies.

Authors:  Ryuji Yamaguchi; Guy Perkins
Journal:  Cancer Res       Date:  2011-11-03       Impact factor: 12.701

3.  Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia.

Authors:  Elaine Holmes; Tsz M Tsang; Jeffrey T-J Huang; F Markus Leweke; Dagmar Koethe; Christoph W Gerth; Brit M Nolden; Sonja Gross; Daniela Schreiber; Jeremy K Nicholson; Sabine Bahn
Journal:  PLoS Med       Date:  2006-08       Impact factor: 11.069

Review 4.  Neural pathways that control the glucose counterregulatory response.

Authors:  Anthony J M Verberne; Azadeh Sabetghadam; Willian S Korim
Journal:  Front Neurosci       Date:  2014-02-26       Impact factor: 4.677

5.  VHL-deficient renal cancer cells gain resistance to mitochondria-activating apoptosis inducers by activating AKT through the IGF1R-PI3K pathway.

Authors:  Ryuji Yamaguchi; Hiroshi Harada; Kiichi Hirota
Journal:  Tumour Biol       Date:  2016-07-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.